Nicolas Hoertel1,2,3,4, Carlos Blanco5, Mark Olfson2, Maria A Oquendo6, Melanie M Wall2,7, Silvia Franco2, Henri Leleu8, Cédric Lemogne3,4, Bruno Falissard9, Frédéric Limosin3,4. 1. Department of Psychiatry, Corentin Celton Hospital, Paris Descartes University, 4 parvis Corentin Celton; 92130 Issy-les-Moulineaux, France. nico.hoertel@yahoo.fr. 2. Department of Psychiatry, New York State Psychiatric Institute/Columbia University, New York, New York, USA. 3. Department of Psychiatry, Assistance Publique-Hôpitaux de Paris (APHP), Corentin Celton Hospital, Paris Descartes University, PRES Sorbonne Paris Cité, Paris, France. 4. INSERM UMR 894, Psychiatry and Neurosciences Center; Paris Descartes University, PRES Sorbonne Paris Cité, Paris, France. 5. Division of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, Bethesda, Maryland, USA. 6. Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 7. Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York, USA. 8. Public Health Expertise, Paris, France. 9. Centre de Recherche en Epidemiologie et Santé des Populations (CESP), Paris-Saclay University, Paris-Sud University, UVSQ, INSERM, APHP, Paris, France.
Authors: Charles Ouazana-Vedrines; Thomas Lesuffleur; Anne Cuerq; Anne Fagot-Campagna; Antoine Rachas; Chrystelle Gastaldi-Ménager; Nicolas Hoertel; Frédéric Limosin; Cédric Lemogne; Philippe Tuppin Journal: Front Psychiatry Date: 2022-09-08 Impact factor: 5.435